iRhythm Holdings, Inc. IRTC is pairing sustained revenue growth with better operating leverage, giving investors a stronger fundamental setup than a year ago. Second-quarter 2026 results showed healthy demand, widening margins and positive free cash flow.

The investment case is not one-sided. Reimbursement exposure, execution in newer channels, the pending Vital Connect acquisition and an unresolved FDA warning letter keep the risk profile elevated. That mix argues for weighing improving fundamentals against still-meaningful execution uncertainty.

IRTC's Q2 Growth Strengthens the Bull Case

IRTC generated second-quarter revenues of $224.2 million, up 20.1% year over year. Growth was driven primarily by sustained volume demand across the customer base, with newer channels adding to the expansion. Revenues also topped the Zacks Consensus Estimate by 2.2%.

The result extended iRhythm's run of more than 20% revenue growth to seven consecutive quarters. Management raised full-year 2026 revenue guidance to $880-$890 million from $875-$885 million, with volume expected to remain the main growth driver.

Image Source: Zacks Investment Research

iRhythm's Margin Gains Improve the Earnings Setup

Profitability improved alongside the top line. Gross margin expanded 160 basis points year over year to 72.8%, helped by operational efficiencies, product mix and scale benefits from higher volumes. Adjusted operating expenses were essentially flat at $145 million.

Adjusted EBITDA reached $43.3 million, or 19.3% of revenues, improving by more than 1,000 basis points year over year. Free cash flow was a record $37.5 million. Scale, workflow optimization, manufacturing automation and disciplined spending are increasingly translating revenue growth into operating leverage.

IRTC's Expansion Strategy Broadens the Opportunity

iRhythm is pushing ambulatory cardiac monitoring beyond traditional cardiology into primary care, value-based care and population health. Innovative channels were its fastest-growing channel in the second quarter, with new partners continuing to join across these settings.

Workflow integration is supporting that expansion. About 60% of second-quarter volume came from electronic health record-integrated accounts, up from roughly 53% in the first quarter, while nearly 80 of the company's top 100 customers were integrated. These connections can reduce ordering friction and support broader adoption.

iRhythm Still Faces Reimbursement and Execution Risks

Reimbursement remains a key uncertainty. In Japan, better reimbursement took effect June 1, but international expansion still requires clinical evidence and market-specific reimbursement progress. Across Europe, reimbursement remains fragmented, while U.S. Medicare and commercial payers continue to scrutinize utilization and cost.